Alkermes plc (NASDAQ:ALKS) Given Consensus Recommendation of “Moderate Buy” by Analysts

Alkermes plc (NASDAQ:ALKS) has been given an average recommendation of “Moderate Buy” by the eleven research firms that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and seven have given a buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $36.70.

Several research analysts have recently commented on the company. StockNews.com raised Alkermes from a “hold” rating to a “buy” rating in a report on Sunday, July 28th. HC Wainwright increased their price target on shares of Alkermes from $35.00 to $37.00 and gave the company a “neutral” rating in a research report on Thursday, July 25th. TD Cowen assumed coverage on shares of Alkermes in a report on Monday, June 17th. They issued a “buy” rating and a $34.00 price objective for the company. Robert W. Baird upped their price objective on shares of Alkermes from $37.00 to $38.00 and gave the company an “outperform” rating in a research note on Thursday, July 25th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $48.00 target price on shares of Alkermes in a research report on Monday, September 16th.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Signaturefd LLC grew its position in shares of Alkermes by 51.2% in the 2nd quarter. Signaturefd LLC now owns 1,417 shares of the company’s stock worth $34,000 after buying an additional 480 shares during the last quarter. Hexagon Capital Partners LLC boosted its holdings in Alkermes by 3,841.0% in the second quarter. Hexagon Capital Partners LLC now owns 1,537 shares of the company’s stock valued at $37,000 after acquiring an additional 1,498 shares in the last quarter. GAMMA Investing LLC increased its position in Alkermes by 44.4% during the 2nd quarter. GAMMA Investing LLC now owns 2,287 shares of the company’s stock valued at $55,000 after purchasing an additional 703 shares during the period. CWM LLC increased its position in Alkermes by 36.7% during the 1st quarter. CWM LLC now owns 2,732 shares of the company’s stock valued at $74,000 after purchasing an additional 733 shares during the period. Finally, Ashton Thomas Private Wealth LLC bought a new position in Alkermes in the 2nd quarter worth $116,000. Hedge funds and other institutional investors own 95.21% of the company’s stock.

Alkermes Trading Up 3.0 %

Shares of ALKS opened at $28.83 on Friday. Alkermes has a twelve month low of $22.01 and a twelve month high of $32.88. The stock has a market cap of $4.88 billion, a PE ratio of 11.40, a P/E/G ratio of 0.59 and a beta of 0.46. The company has a quick ratio of 2.61, a current ratio of 2.99 and a debt-to-equity ratio of 0.22. The business’s 50-day moving average price is $27.45 and its 200-day moving average price is $25.73.

Alkermes (NASDAQ:ALKS) last posted its earnings results on Wednesday, July 24th. The company reported $0.70 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.70. The business had revenue of $399.13 million for the quarter, compared to analysts’ expectations of $393.30 million. Alkermes had a net margin of 19.15% and a return on equity of 23.20%. The business’s revenue for the quarter was down 35.4% compared to the same quarter last year. During the same period in the prior year, the company posted $0.38 EPS. On average, equities analysts forecast that Alkermes will post 2.36 EPS for the current fiscal year.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.